Biota Holdings Limited

Biota is a leading anti-infective drug development company based in MelbourneAustralia, with key expertise in respiratory diseases, particularly influenza.  Biota developed the first-in-class neuraminidase inhibitor, zanamivir, subsequently marketed by GlaxoSmithKline as Relenza.  Biota research breakthroughs include a series of candidate drugs aimed at treatment of respiratory syncytial virus (RSV) disease and Hepatitis C (HCV) virus infections.  Biota has clinical trials underway with its lead compound for human rhinovirus (HRV) infection in patients with compromised respiration or immune systems.

In addition, Biota and Daiichi Sankyo co-own a range of second generation influenza anti-virals, of which the lead product lnavir®, is approved for marketing in Japan.

Relenza™ is a registered trademark of the GlaxoSmithKline group of companies.

Latest Media Releases

Latest News

Market Reports / by - 9 years ago

Midday: Shares in positive territory

04 Feb 2011 - Shares in positive territory. Peter Crane, a member of the Crane Group Ltd’s (Public, ASX:CRG) founding family has taken to the internet to persuade shareholders to r…

Stock Watch / by - 10 years ago

Stock Watch - 05/07/10

Investment advisor James Gerrish takes a technical look at Dow Jones, FTSE 100, S&P ASX200, Financial Sector, RIO, GNS, BTA, ORG, TLS, CBA, BHP, QBE, MAP, Buy Hold Sell Recommendat…

Stock Watch / by - 10 years ago

Stock Watch - 15/03/10

Trading manager James Gerrish takes a technical look at the S&P500, China's SSE Composite, CTX, RIO, DJS, BTA, AIO, MND, BOW, ESG, SUN, WPL, BKN, EQN, CEY, MCC, and FMG.